TIDMSLN

RNS Number : 7525Y

Silence Therapeutics PLC

24 August 2018

Silence Therapeutics Notice of Interim Results

24 AUGUST 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, will announce results for the six months ending 30 June 2018 on Tuesday 11 September 2018.

Dr. David Horn Solomon, Chief Executive Officer and David Ellam, Chief Financial Officer, will host a live conference call for analysts at 12.00pm BST on the day of the results.

Enquiries:

 
 Silence Therapeutics plc                           Tel: +44 (0) 20 3457 
  Dr. David Horn Solomon, Chief Executive Officer                   6900 
  Dr. Andy Richards CBE, Interim Chair 
  David Ellam, Chief Financial Officer 
 Peel Hunt LLP (Nominated Adviser and Broker)       Tel: +44 (0) 20 7418 
  James Steel/ Oliver Jackson                                       8900 
 European IR                                        Tel: +44 (0) 20 3709 
  Consilium Strategic Communications                                5700 
  Mary-Jane Elliott, Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                                 Tel: +1 (212) 213 
  Burns McClellan                                                   0006 
  Lisa Burns, John Grimaldi, Jill Steier 
  silence.therapeutics@burnsmc.com

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORDMGZRVFGGRZM

(END) Dow Jones Newswires

August 24, 2018 02:01 ET (06:01 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Silence Therapeutics Charts.